TR201807128T4 - Viral vektör imalatı. - Google Patents

Viral vektör imalatı. Download PDF

Info

Publication number
TR201807128T4
TR201807128T4 TR2018/07128T TR201807128T TR201807128T4 TR 201807128 T4 TR201807128 T4 TR 201807128T4 TR 2018/07128 T TR2018/07128 T TR 2018/07128T TR 201807128 T TR201807128 T TR 201807128T TR 201807128 T4 TR201807128 T4 TR 201807128T4
Authority
TR
Turkey
Prior art keywords
cell
cells
cho
virus
sequence
Prior art date
Application number
TR2018/07128T
Other languages
English (en)
Turkish (tr)
Inventor
Michael Howley Paul
Liu Liang
Original Assignee
Sementis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904242A external-priority patent/AU2013904242A0/en
Application filed by Sementis Ltd filed Critical Sementis Ltd
Publication of TR201807128T4 publication Critical patent/TR201807128T4/tr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151Methods of production or purification of viral material
    • C12N2710/24152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TR2018/07128T 2013-11-01 2014-11-03 Viral vektör imalatı. TR201807128T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2013904242A AU2013904242A0 (en) 2013-11-01 Viral vector manufacture
AU2014900370A AU2014900370A0 (en) 2014-02-07 Orthopox vectors and propagation

Publications (1)

Publication Number Publication Date
TR201807128T4 true TR201807128T4 (tr) 2018-06-21

Family

ID=53003022

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/07128T TR201807128T4 (tr) 2013-11-01 2014-11-03 Viral vektör imalatı.

Country Status (24)

Country Link
US (2) US10544397B2 (enExample)
EP (2) EP3375882B1 (enExample)
JP (2) JP6682443B2 (enExample)
KR (1) KR102047030B1 (enExample)
CN (1) CN106255758B (enExample)
AU (1) AU2014344738B2 (enExample)
CA (1) CA2931518C (enExample)
CY (1) CY1121414T1 (enExample)
DK (2) DK3063278T3 (enExample)
ES (1) ES2670034T3 (enExample)
HR (1) HRP20180789T1 (enExample)
HU (1) HUE037718T2 (enExample)
LT (1) LT3063278T (enExample)
NO (1) NO3063278T3 (enExample)
NZ (1) NZ720241A (enExample)
PL (1) PL3063278T3 (enExample)
PT (1) PT3063278T (enExample)
RS (1) RS57290B1 (enExample)
RU (1) RU2658487C2 (enExample)
SG (1) SG11201603919XA (enExample)
SI (1) SI3063278T1 (enExample)
SM (1) SMT201800267T1 (enExample)
TR (1) TR201807128T4 (enExample)
WO (1) WO2015061858A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI728173B (zh) * 2016-08-19 2021-05-21 澳大利亞商賽門堤斯有限公司 病毒疫苗
JP2018081568A (ja) * 2016-11-17 2018-05-24 グローリー株式会社 紙幣収納装置および紙幣処理機
CA3258751A1 (en) * 2022-06-30 2024-01-04 Bavarian Nordic As Mammalian cell line for the production of modified Ankara vaccine virus (MVA)
EP4590841A2 (en) * 2022-09-20 2025-07-30 Aldevron, LLC Best1 vectors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604183B1 (fr) * 1986-09-23 1988-12-30 Transgene Sa Sequence d'adn, vecteurs, virus recombinants et procede mettant en oeuvre des virus de la vaccine recombinants capables de se multiplier dans les cellules cho
EP0758397B1 (en) * 1994-04-29 2005-06-22 Baxter Healthcare S.A. Recombinant poxviruses with foreign polynucleotides in essential regions
DE60336653D1 (de) * 2002-08-07 2011-05-19 Bavarian Nordic As Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
AU2007280004A1 (en) * 2006-08-04 2008-02-07 Dublin City University A method of producing recombinant biological products

Also Published As

Publication number Publication date
SG11201603919XA (en) 2016-07-28
CY1121414T1 (el) 2020-05-29
CN106255758B (zh) 2020-06-23
JP2016534755A (ja) 2016-11-10
RU2658487C2 (ru) 2018-06-21
EP3063278A4 (en) 2017-04-12
CA2931518A1 (en) 2015-05-07
HUE037718T2 (hu) 2018-09-28
CN106255758A (zh) 2016-12-21
AU2014344738B2 (en) 2019-03-21
WO2015061858A1 (en) 2015-05-07
CA2931518C (en) 2021-03-09
EP3375882A1 (en) 2018-09-19
PT3063278T (pt) 2018-05-25
NZ720241A (en) 2019-10-25
EP3375882B1 (en) 2019-10-16
DK3375882T3 (da) 2019-12-16
US20200190482A1 (en) 2020-06-18
RS57290B1 (sr) 2018-08-31
EP3063278A1 (en) 2016-09-07
DK3063278T3 (en) 2018-06-06
SMT201800267T1 (it) 2018-07-17
US20170029784A1 (en) 2017-02-02
RU2016121425A (ru) 2017-12-04
EP3063278B1 (en) 2018-02-28
AU2014344738A1 (en) 2016-06-09
PL3063278T3 (pl) 2018-08-31
KR20160079868A (ko) 2016-07-06
JP2020039340A (ja) 2020-03-19
ES2670034T3 (es) 2018-05-29
KR102047030B1 (ko) 2019-11-20
HK1223395A1 (en) 2017-07-28
SI3063278T1 (sl) 2019-04-30
NO3063278T3 (enExample) 2018-07-28
LT3063278T (lt) 2018-07-10
US10544397B2 (en) 2020-01-28
HRP20180789T1 (hr) 2018-09-07
JP6682443B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
AU2019377141B2 (en) Enhanced systems for cell-mediated oncolytic viral therapy
KR20170048396A (ko) 재조합 변형된 백시니아 바이러스 앙카라 (mva) 필로바이러스 백신
JP2020039340A (ja) ウイルスベクターの作製
CN110066769B (zh) 用于改善的病毒生产的禽类细胞
CN110951699B (zh) 表达犬瘟热病毒结构蛋白的重组狂犬病病毒及其应用
CN101586120A (zh) 狂犬病病毒Flury-LEP疫苗株反向遗传操作系统及LEP绿色荧光蛋白重组病毒载体
CN105039268A (zh) 表达鸭坦布苏病毒e蛋白的重组鸭瘟病毒及其构建方法和应用
JP2021518152A (ja) 標的タンパク質を安定して発現できる組換えウイルス
EP4331676A2 (en) Viral vaccines
CN101768575B (zh) 双表达g基因的重组狂犬病病毒的构建及其生物学特性分析
JP2021533791A (ja) ウイルスを生成する方法及び組成物
CN109750006A (zh) 一种犬瘟热病毒复制缺陷毒株及其构建方法
HK1260426A1 (en) Viral vector manufacture
HK1260426B (en) Viral vector manufacture
EP3668988B1 (en) Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
HK1223395B (en) Viral vector manufacture
WO2024245722A2 (en) Rapid selection system for the generation of recombinant enveloped viruses
CN102417907B (zh) 靶向抑制羊痘病毒ORF095基因的siRNA序列
CN102851293B (zh) 靶向抑制羊痘病毒ORF095基因的序列siRNA-165
CN102796740A (zh) 靶向抑制羊痘病毒ORF095基因的序列siRNA-70